Compare iShares MSCI South Africa ETF (EZA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI South Africa ETF trades at $62.85, while Regeneron Pharmaceuticals Inc trades at $675.62 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while iShares MSCI South Africa ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals.
| EZA | REGN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $812.27 |
52-Week Low | $53.05 | $542.52 |
Market Cap | — | $69.66B |
Enterprise Value | — | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
